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Abstract
Objective To compare estimates of intervention effects between single
centre and multicentre randomised controlled trials with continuous
outcomes.
Design Meta-epidemiological study.
Data sources 26 meta-analyses totalling 292 randomised controlled
trials (177 single centre, 115 multicentre) with continuous outcomes
published between January 2007 and January 2010 in the Cochrane
database of systematic reviews.
Data extraction Data were extracted on characteristics of trials, single
or multicentre status, risk of bias using the risk of bias tool of the
Cochrane Collaboration, and results.
Data synthesis The intervention effects were estimated with
standardised mean differences. For each meta-analysis, random effects
meta-regression was used to estimate the difference in standardised
mean differences between single centre and multicentre trials.
Differences in standardised mean differences were then pooled across
meta-analyses by a random-effects meta-analysis model. A combined
difference in standardised mean differences of less than 0 indicated that
single centre trials showed larger treatment effects, on average, than
did multicentre trials. Because single centre trials may be more prone
to publication bias and may have lower methodological quality than
multicentre trials, sensitivity analyses were done with adjustment for
sample size and domains of the risk of bias tool.
Results Single centre trials showed larger intervention effects than did
multicentre trials (combined difference in standardised mean differences
−0.09, 95% confidence interval −0.17 to −0.01, P=0.04), with low
heterogeneity across individual meta-analyses (I
2=0%, between
meta-analyses variance τ
2=0.00). Adjustment for sample size slightly
attenuated the difference (−0.08, −0.17 to 0.01). Adjustment for risk of
bias yielded similar estimates with wider confidence intervals, some of
them crossing 0 (−0.09, −0.17 to 0.00 for overall risk of bias).
Conclusions On average, single centre clinical trials with continuous
outcomes showed slightly larger intervention effects than did multicentre
trials. Further research is needed to investigate potential causes of these
differences.
Introduction
Empirical evidence shows that lack of allocation concealment,
lack of blinding, or excluding patients from the analysis may
lead to an underestimation or overestimation of the true
interventioneffect.
1-8Suchempiricalevidenceisoftenbasedon
meta-epidemiological studies, which use a collection of
meta-analyses to explore the influence of specific
methodological characteristics of a trial, such as flaws in trial
design or conduct, on the estimates of treatment effect.
9
Another trial characteristic that could be associated with
intervention effect estimates is the status of the study centres,
whether the trial is carried out in a single centre or in several
centres (multicentre). One study
10 warned against the validity
of single centre trials in critical care medicine because the
positive results of many single centre trials were frequently
contradictedwhentestedinmulticentresettings.Morerecently,
a meta-epidemiological study of binary outcomes showed that
intervention effects were on average larger in single centre
randomised trials than in multicentre trials.
11
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Research
RESEARCHAccording to a recent methodological study of a representative
sample of randomised controlled trials, binary outcomes
represented only 28% of all outcomes reported and continuous
outcomes 69%.
12 Results for binary outcomes may not be
extrapolated to trials assessing continuous outcomes because
such trials usually differ in medical condition, risk of bias,
sample size, and statistical analysis. We carried out a
meta-epidemiological study to compare intervention effect
estimatesfromsinglecentreandmulticentretrialsthatevaluated
a continuous end point.
Methods
We searched for eligible meta-analyses published between 1
January 2007 and 1 January 2010 in the Cochrane database of
systematic reviews using a previous search strategy
13:
“standardised mean difference” OR “standardized mean
difference”OR“SMD”OR“effectsize”OR“meandifference”
in the title, abstract, or keywords. We focused on Cochrane
meta-analyses because studies have shown that these have high
methodological quality, are well reported, and are associated
with fewer conflicts of interest than are non-Cochrane
meta-analyses.
14-16
Study selection
Prespecified eligibility criteria were systematic reviews
including at least one meta-analysis of a continuous primary
outcome,asdefinedbytheauthorsoftheCochranereview,and
assessing the effect of therapeutic interventions for at least five
randomised controlled trials. If the systematic review included
several meta-analyses with multiple continuous outcomes and
didnotspecifyaprimaryoutcome,weselectedthemeta-analysis
with the highest number of trials. We excluded meta-analyses
ofnon-randomisedcontrolledtrialsaswellasthoseofindividual
patientdata,thoseincludingonlyunpublisheddata,andupdates
of meta-analyses. Meta-analyses in which all trials were single
centre or multicentre could not contribute to the analysis and
were also excluded. Because final value and change scores
should not be combined together as standardised mean
difference,weexcludedmeta-analysesthatoriginallycontained
a mixture of change from baseline and final value scores as
mean differences.
One reviewer selected potentially relevant meta-analyses after
screeningthetitleandabstract,andfulltextifneeded,according
totheprespecifiedeligibilitycriteria.Asecondreviewerchecked
all included and excluded meta-analyses. Disagreements were
resolved by discussion.
All individual randomised controlled trials included in the
meta-analyses were eligible, and the full text for the trials was
systematically searched. If the full text was not available we
excluded the trial. We excluded crossover or cluster trials and
subgroup analyses.
Data extraction
A standardised data collection form was used to collect the
general characteristics and centre status of each trial (single or
multicentre) and to assess the risk of bias from the original
reports of the trials. One reviewer extracted all data. A second
reviewer independently duplicated data extraction and risk of
bias assessment in a random sample of one fifth of the trials,
and consensus was achieved by discussion.
General characteristics of individual trials
For each trial we recorded the general characteristics, such as
year of publication, funding source (public, private, not
reported), and number of patients randomly allocated in each
group. We classified the experimental intervention as
non-pharmacological or pharmacological, with a
non-pharmacologicalinterventionclassifiedasanyintervention
that did not include an active substance.
17 18 We also noted the
type of comparator: placebo, waiting list, no treatment, usual
care, or active treatment.
Two reviewers blinded to the trials and results of the
meta-analysis identified the experimental and control groups
for each eligible meta-analysis according to the objectives in
the individual trials. If the two reviewers could not distinguish
the experimental and control arms, the meta-analysis was
excluded.
Assessment of single centre or multicentre status
in individual trials
We initially relied on the self reporting of single centre or
multicentre statusfor selectedtrials.If the statuswas notclearly
reported in the original report, we systematically contacted the
corresponding author up to three times. In case of no response
we applied the rules that if the report stated both several ethics
committees and different affiliations of authors then we
classified the trial as multicentre, and if the report stated both
a single ethics committee and a single author affiliation then
we classified the trial as single centre. In all other cases we
considered that the status was unclear and excluded the trial
from the analysis.
Assessment of risk of bias in individual trials
As recommended by the Cochrane Collaboration we used the
risk of bias tool to assess the risk of bias from the individual
reports for each trial.
19 The domains assessed separately were
randomsequencegeneration,allocationconcealment,blinding,
incomplete outcome data, and selective outcome reporting.
According to the Cochrane handbook, the item dedicated to
selectivereportingshouldbeassessedbycomparingtheprotocol
and the article to check whether all prespecified outcomes in
the protocol are adequately reported in the article. Because no
protocolwaspublishedandnotrialwasregisteredinoursample,
we could not assess this item appropriately and decided to
disregard it. Each domain was rated as low, high, or unclear for
riskofbias(seewebextraappendix1).Thedomainsforblinding
andincompleteoutcomedatawereassessedattheoutcomelevel
andthuscorrespondedtotheselectedoutcome.Wesummarised
theriskofbiasfortheselectedoutcomewithineachtrial(across
domains). The overall risk of bias was rated as low (low risk of
bias for all domains), high (high risk of bias for one or more
domains), or unclear (unclear risk of bias for one or more
domains).
Results of individual trials
Because errors in data extraction are common for continuous
outcomes,
13 20fivestatisticiansorepidemiologistsextracteddata
on outcomes from the original reports of trials. We extracted
thenumberofanalysedpatientsand,accordingtothereporting,
themeanbaseline,final,andchangescorevalues(andassociated
standarddeviations)forboththeexperimentalandcontrolarms.
The abstracted data were compared with those abstracted in the
meta-analysis report. If the authors of the meta-analysis report
used published data only and if differences were noted, a
reviewer checked the results in the trial reports and in the
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RESEARCHmeta-analysis report with the help of a statistician and
epidemiologistifneededtoreachconsensus.Ifthemeta-analysis
reportspecifiedthattheresultsconcernedunpublisheddata,we
used outcome data abstracted in the meta-analysis report. As
standard deviations were missing in three meta-analyses
(totallingseventrials,
21twotrials,
22andonetrial
23)wefollowed
the imputation method used by the author of the original
meta-analyses—that is, we imputed standard deviations from
other studies in the same meta-analysis.
24
Statistical analysis
Estimation of treatment effect estimates within
each meta-analysis
For each trial we analysed the continuous outcome according
to the analytical method used in the Cochrane meta-analysis,
by analysing final values or change scores as the outcome. We
estimated intervention effects as standardised mean
differences—the difference in mean outcome between groups
divided by a pooled standard deviation within groups. Hedges’
correction for small sample size was applied, whereby we
multiplied the effect measure by a correction factor. Because
ofdifferencesinthedirectionofscales,somestandardisedmean
differences were multiplied by −1 so that a negative effect size
(standardisedmeandifference<0)alwaysindicatedabeneficial
effect for the experimental intervention. If a trial with multiple
intervention groups was included in a meta-analysis, we
combinedthegroupsforasinglepairwisecomparison.
19Within
each meta-analysis we used DerSimonian and Laird random
effects models to combine intervention effects across trials. To
assess heterogeneity across trials we used the Cochran χ
2
homogeneity test, Higgins’ I² coefficient, and the between trial
variance estimate τ².
Meta-epidemiological analysis
The meta-epidemiological analysis relied on previously
described methodology.
9 For each meta-analysis we estimated
the difference in standardised mean differences between single
centreandmulticentretrialsusingrandomeffectsmetaregression
toincorporateheterogeneitybetweentrials.Thenwesynthesised
the differences in standardised mean differences across
meta-analyses using a random effects meta-analysis model.
Resultsarereportedasthemeandifferenceinstandardisedmean
differences between single centre and multicentre trials, with
associated 95% confidence intervals. A combined difference in
standardised mean differences of less than 0 indicated that on
averagesinglecentretrialsshowedlargertreatmenteffectsthan
did multicentre trials. We used the I² statistic, Cochran’s Q χ
2
test, and the between meta-analyses variance τ² to assess
heterogeneity across differences in standardised mean
differences. The type of intervention (pharmacological versus
non-pharmacological) was a prespecified subgroup analysis.
We carried out an interaction test using a random effects
metaregression model to assess whether the difference in
standardised mean differences varied by type of intervention.
Sensitivity analyses
To control for potential confounding we adjusted the
metaregression models for important trial characteristics and
re-evaluated the combined difference in standardised mean
differences.
Because single centre trials may be more prone to publication
bias than multicentre trials, we adjusted the metaregression
model on the number of patients randomly allocated as a
continuous variable, and as a binary variable with a cut-off of
100 patients per arm; a recent study
25 showed that results were
more beneficial in trials with fewer than 100 patients per arm
than in trials with more than 100 patients per arm.
Tocontrolforpotentialconfoundingbymethodologicalquality
and funding, we adjusted on the different domains of the risk
of bias tool (random sequence generation and allocation
concealment, blinding, incomplete outcome data), as well as
the overall risk of bias within trials and the funding source
(public, private, or not reported).
All analyses were done using Stata MP v10.0 with the metan
and metareg subroutines.
Results
Characteristics of selected meta-analyses
Among 539 potentially eligible meta-analyses from the
Cochrane database of systematic reviews, 26 were
selected.
21-23 26-48 These meta-analyses included 306 trials, and
292 trials contributed to the analysis after exclusions (fig 1⇓).
The meta-analyses concerned a wide range of medical areas.
(See web extra appendix 2 for the characteristics of the
meta-analyses.) All but three meta-analyses had a subjective
outcome. The median number of trials included per
meta-analysis was 9 (range 5-33), and the median number of
patients analysed per meta-analysis was 719 (range 184-4683).
Thecombinedstandardisedmeandifferencevariedfrom−1.45
to−0.04(median−0.38).Fourteenmeta-analyses(52%)showed
substantial heterogeneity (I
2 ≥50%).
Sixteen meta-analyses involving 173 trials assessed
non-pharmacological interventions. All but one concerned
psychologicaloreducationalinterventions.Themediannumber
of trials was 8 (range 5-33), and the median number of patients
analysed was 546 (184-4683).
Tenmeta-analysesinvolving119trialsassessedpharmacological
interventions.Themediannumberoftrialswas12(range5-27),
and the median number of patients analysed was 1051
(310-2225).
Characteristics of single centre and
multicentre trials
Among the 292 trials contributing to the analysis, 177 were of
single centre status and 115 multicentre status. Information
about the centre status of the trial was unclear in 21 articles, so
the corresponding author was contacted, and information was
obtained for nine. A further eight trials were classified using
the number of ethics committees and the affiliations of authors.
The four remaining trials were excluded from the analysis.
In total, 63% of single centre and 54% of multicentre trials
assessedanon-pharmacologicalintervention.Multicentretrials
tended to be published more recently than single centre trials.
Themediannumberofrandomisedpatientswas50(interquartile
range 30-77) for single centre trials and 122 (60-235) for
multicentre trials (P=0.02). More multicentre trials than single
centre trials showed a low risk of bias for sequence generation
(52% v 36%, P=0.15) and allocation concealment (30% v 12%,
P=0.07); 59% of single centre trials and 64% of multicentre
trials showed a high risk of bias for incomplete outcome data.
Single centre trials had a lower rate of low overall risk of bias
than did multicentre trials (3% v 9%, P=0.23; table⇓).
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RESEARCHEstimates of treatment effect differences
between single centre and multicentre trials
Treatment effects were on average more beneficial in single
centre trials than in multicentre trials (combined difference in
standardised mean differences −0.09, 95% confidence interval
−0.17 to −0.01, P=0.04; fig 2⇓). The estimated differences in
standardised mean differences were negative for 19
meta-analyses and positive for seven meta-analyses.
Heterogeneityacrossindividualmeta-analyseswaslow(I
2=0%,
between meta-analysis variance τ
2=0.00).
Subgroup analysis
For the 16 meta-analyses assessing non-pharmacological
interventions, the combined difference in standardised mean
differences was −0.08 (95% confidence interval −0.18 to 0.01,
P=0.07, I
2=0%, between meta-analysis variance τ
2=0.00). For
the 10 meta-analyses assessing pharmacological interventions,
the combined difference in standardised mean differences was
−0.11 (95% confidence interval −0.29 to 0.08, P=0.27, I
2=0%,
betweenmeta-analysisvarianceτ
2=0.00).Thetestofinteraction
between non-pharmacological and pharmacological trials was
not significant (P=0.84).
Sensitivity analyses
Figure 3⇓ shows the results of sensitivity analyses. Adjustment
for the different domains of the risk of bias tool and the overall
risk of bias yielded similar estimates, with slightly wider
confidence intervals, crossing 0 for sequence generation,
blinding, incomplete outcome data, and overall risk of bias
(combined difference in standardised mean differences for
overall risk of bias −0.09, 95% confidence interval −0.17 to
0.00). Adjustment on funding yielded consistent results
(combined difference in standardised mean differences −0.09,
95% confidence interval −0.18 to −0.01). Adjustment for the
numberofpatientsrandomlyallocatedattenuatedthedifference
between single centre and multicentre trials: −0.06 (−0.16 to
0.04) as a continuous variable and −0.08 (−0.17 to 0.01) as a
binary variable, with the cut-off of 100 patients per arm.
Discussion
We carried out a meta-epidemiological study of 26
meta-analyses of 292 randomised controlled trials comparing
estimatesofinterventioneffectforsinglecentreandmulticentre
trials assessing a continuous outcome. Our results showed on
average slightly larger intervention effect estimates in single
centre trials than in multicentre trials, with low heterogeneity
across individual meta-analyses. Similar results were found in
the prespecified subgroups of non-pharmacological and
pharmacological interventions. Results tended to be consistent
after adjusting for risk of bias and funding source. Adjustment
for the number of patients randomly allocated resulted in an
attenuation of this difference.
Themagnitudeoftheobserveddifferenceinstandardisedmean
differences between single centre and multicentre trials may
seem small. The average difference corresponded to about one
quarter of a typical effect found for interventions in our
collection of meta-analyses: the combined standardised mean
difference varied from −1.45 to −0.04 across the 26
meta-analyses, with a median of −0.38.
Strengths and limitations of the study
Our selection of meta-analyses concerned a large number of
recently published meta-analyses covering a wide range of
medical areas, for a more generalisable sample than when
focusing on a particular topic. We selected meta-analyses
published in the Cochrane database of systematic reviews
because they are of higher methodological quality, are better
reported, and have fewer conflicts of interest than do
non-Cochrane meta-analyses.
14-16 Overall we found low
heterogeneity across individual meta-analyses. We carried out
severalsensitivityanalysesbyadjustingmetaregressionmodels
on important covariates, which is not commonly done in
meta-epidemiologicalstudies.Ourresultstendedtobeconsistent
afteradjustmentforsamplesize,riskofbias,andfundingsource.
Ourstudycontainssomelimitations.Firstly,oursearchstrategy
may not have been exhaustive, but our aim was to provide a
representative sample of meta-analyses. We excluded updates
ofmeta-analysesbecause,althoughtheyarethemostcomplete,
theymighthavelessdetailthantheoriginalreport.Nevertheless,
this choice should not have biased our results. Secondly, our
sensitivity analyses to control for meta-confounding may also
havelimitations.Theriskofbiasdomainswerepoorlyreported
and discrepancies may exist between the reported quality and
what actually occurred.
49 In particular, we were unable to
appropriatelyassesstheriskofselectiveoutcomereportingbias
because none of the selected trials was registered and study
protocolswerenotavailable,whichprecludedassessingwhether
prespecified (primary and secondary) outcomes were reported.
Moreover,thedimensionsofwithintrialriskofbiasarepossibly
associated with each other and with other trial characteristics,
such as single centre status. However, methods to correct for
multiple dimensions of quality require further development.
Comparison with other studies
Heterogeneity of intervention effect estimates between single
centre and multicentre trials has been poorly explored
50 and is
not taken into account when assessing the risk of bias or the
level of evidence in trials.
10 In 1986 a study
50 assessed a sample
of 246 comparative clinical trials of cancer (not necessarily
randomised) and found by a random effects model adjusted for
samplesizethatsinglecentretrialstendedtoshowlargereffects
for survival than did multicentre trials.
50 More recently, a
meta-epidemiological study
11 of 48 meta-analyses showed
significantly larger intervention effect estimates for binary
outcomesinsinglecentretrialsthaninmulticentretrials,which
persisted after adjustment for the number of patients randomly
allocated and risk of bias. The two collections of meta-analyses
differed in terms of medical specialties and types of outcomes.
In fact the collection involving binary outcomes contained a
high representation of cardiovascular research, and we selected
the most objective outcomes (such as all cause mortality or the
result of a biological test if reported), but in the collection
involvingcontinuousoutcomes,severalmeta-analysesconcerned
psychological and behavioural research, and most outcomes
were subjective.
Possible mechanisms
The larger intervention effects we observed for single centre
trials than for multicentre trials may be explained by several
mechanisms. The first may be due to “small study effects”: the
tendency for smaller studies in a meta-analysis to show larger
intervention effects.
25 As expected, we found that the single
centre trials were of a smaller sample size than the multicentre
trials. Our results were slightly attenuated after adjusting for
the number of patients randomly allocated as a continuous
variable.Nevertheless,whenadjustingforthenumberofpatients
randomly allocated as a binary variable, with the previously
recommended cut-off of 100 patients per arm,
25 we obtained
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RESEARCHsimilar estimates, although the confidence interval was slightly
wider and crossed 0. Publication bias could also contribute to
the observed differences in treatment effect estimates between
singlecentreandmulticentretrials.Therelationsbetweencentre
status and publication bias were explored in some studies
51-53:
twofoundnosignificantassociationbetweensinglecentrestatus
and publication bias,
51 53 but a more recent study found
multicentre status independently associated with full
publication.
52 The association of single centre and multicentre
trials and intervention effect may also be confounded by
methodological quality. We found that more multicentre trials
were at low risk of bias for the risk of bias domains of sequence
generation and allocation concealment than single centre trials.
After adjusting for each domain of the risk of bias tool as well
as overall risk of bias, we obtained similar estimates with
slightlywiderconfidenceintervals,somecrossing0.Thelarger
intervention effect could also be due to different mechanisms
for selection of a more homogeneous (highly selected)
population in single centre than in multicentre trials,
standardised interventions, and higher expertise of teams in
single centre trials.
54 Further studies are needed to explore the
role and impact of these different mechanisms, but probably
several reasons act together to contribute to the larger
intervention effect observed in single centre trials.
Conclusions and implications
Intervention effect estimates were on average slightly larger in
single centre randomised controlled trials than in multicentre
randomised controlled trials assessing continuous outcomes.
The reasons for these larger effect sizes in single centre trials
need to be explored in further studies.
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Table 1| Characteristics of single centre and multicentre randomised controlled trials. Values are numbers (percentages) unless stated
otherwise
P value* Multicentre trials (n=115) Single centre trials (n=177) Characteristics
Interventions:
0.35 53 (46) 66 (37) Pharmacological
62 (54) 111 (63) Non-pharmacological
Funding:
0.13 42 (36) 60 (34) Public
41 (36) 38 (21) Private
32 (28) 79 (45) Not reported
0.02 122 (60-235) 50 (30-77) Median (interquartile range) No of patients randomly assigned
No of patients randomly assigned:
<0.001 22 (19) 90 (51) ≤50
25 (22) 56 (32) 51-100
33 (29) 20 (11) 101-200
35 (30) 11 (6) >200
Year of publication:
0.17 9 (8) 35 (20) 1957-89
47 (41) 53 (30) 1990-9
59 (51) 89 (50) 2000-8
Risk of bias tool:
Sequence generation
0.15 1 (1) 0 (0) High risk of bias
60 (52) 63 (36) Low risk of bias
54 (47) 114 (64) Unclear risk of bias
Allocation concealment:
0.07 13 (11) 22 (12) High risk of bias
34 (30) 22 (12) Low risk of bias
68 (59) 133 (76) Unclear risk of bias
Blinding:
0.39 49 (43) 90 (51) High risk of bias
66 (57) 87 (49) Low risk of bias
0 (0) 0 (0) Unclear risk of bias
Incomplete outcome data:
0.46 74 (64) 104 (59) High risk of bias
24 (21) 30 (17) Low risk of bias
17 (15) 43 (24) Unclear risk of bias
Overall risk of bias:
0.23 96 (83) 141 (80) High risk of bias
10 (9) 5 (3) Low risk of bias
9 (8) 31 (17) Unclear risk of bias
*P values associated with cluster adjusted χ
2 or t tests.
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Fig 1 Selection of meta-analyses and randomised controlled trials
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RESEARCHFig 2 Difference in intervention effect estimates between single centre and multicentre randomised controlled trials. A
combined difference in standardised mean differences <0 indicates that single centre trials yielded larger estimates of
intervention effect than did multicentre trials
Fig 3 Sensitivity analyses showing difference in intervention effect estimates between single centre and multicentre trials
adjusted for sample size, domains of risk of bias tool, and funding
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